MedTrace Logo

Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma

NCT05888636 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-03-22

No results posted yet for this study

Summary

Multiple Myeloma (MM) is the more common hematological neoplastic disease second only to Hodgkin lymphoma. In MM patients, mutated genes are mainly KRAS (23%), NRAS (20%), FAM46C (11%), DIS3 (11%) e TP53 (8%). Epigenetics studies suggested that Changes in histone modifications and DNA methylation pattern, as well as non-coding RNAs (miRNAs) expression are involved in MM development. In particular, it has been shown that the aberrant expression of different miRNAs could discriminate healthy from ill patients. Unfortunately, the main critical issue for an effective treatment of MM is the intrinsic or acquired resistance to pharmacological treatments, due also to a plasmacellular clonal heterogeneity.

The prospective study will involve a patient cohort with MGUS, MM smouldering and MM, with the aim to characterize different transcriptional and epigenetic features, also including miRNAs, among MM cells susceptible or resistant to conventional therapies. The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies.

Conditions

Interventions

OTHER

ChIP-seq, NGS, ATAC-seq

Bone narrow sampling

Sponsors & Collaborators

  • Campus Bio-Medico University

    collaborator OTHER

  • University of Rome Tor Vergata

    collaborator OTHER

  • Sant'Eugenio Hospital, Rome

    collaborator UNKNOWN

  • Regina Elena Cancer Institute

    lead OTHER

Principal Investigators

  • Maurizio Fanciulli, PhD · IRCCS "Regina Elena" National Cancer Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2023-11-11
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05888636 on ClinicalTrials.gov